Shares of medical device-related companies are trading lower after HCA Healthcare noted a Q2 increase in uninsured patient volumes and a decline in surgical volume, which may dim the outlook for device pricing power and margins.

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

Abbott (ABT) declined 2.2% to $111.59 in the latest trading session, underperforming the S&P 500's 0.72% gain. Despite the daily decline, the company has appreciated 5.65% over the past month. Analysts project strong earnings growth with expected EPS of $1.43 (up 10% YoY) and quarterly revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank of #3 (Hold) with a Forward P/E of 20.66, trading at a slight discount to its industry average.

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

Laboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider

The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

8-K filing — BAXTER INTERNATIONAL INC (BAX)

Filed: 2026-08-19 AccNo: 0001193125-26-356188 Size: 323 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Baxter International Announces Appointment Of John Rogers As CFO Effective October 1